Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
More than 1.2 million spinal surgeries are performed in the U.S. each year, including spinal fusion, decompression and discectomy procedures, according to the National Center for Health Statistics. And the volume of elective lumbar fusions is rising across the U.S., research published in Spine indicates.
As spine fusion volumes increase, so do the numbers of patients who will develop pseudarthrosis, a related complication. A number of surgeons are turning to advanced techniques to help reduce non-union rates and the resulting expenditures. For instance, bone grafts are used in 59 percent of lumbar spinal fusion procedures and 91 percent of cervical spinal fusion procedures, according to GlobalData published in 2017.
“There’s a ton of biologics everywhere, and companies are continually approaching surgeons trying to get them to use or switch to their ‘better’ or ‘improved’ biologic,” said Pierce Nunley, MD, director of the Shreveport-based Spine Institute of Louisiana.
Because of all this noise, Dr. Nunley paid little mind at first when a Netherlands-based company called Kuros Biosciences came knocking. But then he saw Kuros’ work on a novel fibrin parathyroid hormone-based bone graft product candidate, which recently received Investigational New Drug approval from the FDA. This product made him realize the company wasn’t approaching biologics like the other vendors; it was taking a much more scientific approach. That’s when he learned about MagnetOs bone graft.
“[Kuros] showed me some real data,” Dr. Nunley said. “And I thought, ‘Wow. That’s pretty compelling.’ So, quite frankly, that’s why I started using MagnetOs.”
Research examining how MagnetOs facilitated bone formation through cell differentiation is what convinced Dr. Nunley that the product was worth its salt for use in spinal fusions. In animal models, MagnetOs formed a bone fusion mass that was comparable — if not better — than other calcium phosphates, he said.